TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.
TECregen has raised $12.5M in total funding. The most recent round was Seed. The last funding was announced in January 2026.
TECregen's investors include HTGF (High-Tech Gruenderfonds), Boehringer Ingelheim Venture Fund, Zürcher Kantonal Bank, Carma Fund, Lifespan Vision Ventures.
TECregen is headquartered in Basel, Switzerland.
TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses.
TECregen is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TECregen — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/tecregen. Accessed August 13, 2026.
VCBacked. (2026). TECregen — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/tecregen
{{cite web |title=TECregen — Funding & Investors |url=https://www.vcbacked.co/company/tecregen |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated